Albireo Pharma, Inc. (NASDAQ:ALBO) CFO Sells $77,788.80 in Stock

Albireo Pharma, Inc. (NASDAQ:ALBO – Get Rating) CFO Simon N.R. Harford sold 1,776 shares of Albireo Pharma stock in a transaction dated Thursday, January 19th. The shares were sold at an average price of $43.80, for a total value of $77,788.80. Following the completion of the transaction, the chief financial officer now owns 32,791 shares of the company’s stock, valued at approximately $1,436,245.80. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Albireo Pharma Stock Down 0.2 %

ALBO stock opened at $43.81 on Monday. The business has a 50 day moving average price of $25.87 and a 200 day moving average price of $22.52. The stock has a market cap of $906.91 million, a price-to-earnings ratio of -6.52 and a beta of 0.81. Albireo Pharma, Inc. has a fifty-two week low of $16.02 and a fifty-two week high of $44.40.

Albireo Pharma (NASDAQ:ALBO – Get Rating) last posted its earnings results on Tuesday, November 8th. The biopharmaceutical company reported ($1.89) earnings per share for the quarter, missing the consensus estimate of ($1.86) by ($0.03). The business had revenue of $9.83 million for the quarter, compared to analysts’ expectations of $9.68 million. Albireo Pharma had a negative return on equity of 97.13% and a negative net margin of 228.51%. As a group, sell-side analysts anticipate that Albireo Pharma, Inc. will post -7.86 EPS for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on ALBO. StockNews.com began coverage on Albireo Pharma in a research note on Wednesday, October 12th. They issued a “sell” rating for the company. Guggenheim cut Albireo Pharma from a “buy” rating to a “neutral” rating in a research note on Wednesday, January 11th. Jefferies Financial Group cut Albireo Pharma from a “buy” rating to a “hold” rating and decreased their price objective for the company from $49.00 to $42.00 in a research note on Wednesday, January 11th. Robert W. Baird lifted their price objective on Albireo Pharma from $43.00 to $55.00 and gave the company an “outperform” rating in a research note on Wednesday, October 12th. Finally, Cowen cut Albireo Pharma from an “outperform” rating to a “market perform” rating and decreased their price objective for the company from $68.00 to $48.00 in a research note on Wednesday, January 11th. One research analyst has rated the stock with a sell rating, six have issued a hold rating and one has issued a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $48.00.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the company. Chicago Capital LLC increased its position in Albireo Pharma by 21.7% during the fourth quarter. Chicago Capital LLC now owns 1,362,484 shares of the biopharmaceutical company’s stock worth $29,443,000 after buying an additional 242,710 shares during the period. Birchview Capital LP increased its position in Albireo Pharma by 3.5% during the third quarter. Birchview Capital LP now owns 117,000 shares of the biopharmaceutical company’s stock worth $2,265,000 after buying an additional 4,000 shares during the period. M&T Bank Corp increased its position in Albireo Pharma by 17.0% during the third quarter. M&T Bank Corp now owns 24,962 shares of the biopharmaceutical company’s stock worth $484,000 after buying an additional 3,632 shares during the period. Jane Street Group LLC increased its position in Albireo Pharma by 152.7% during the third quarter. Jane Street Group LLC now owns 61,652 shares of the biopharmaceutical company’s stock worth $1,194,000 after buying an additional 37,252 shares during the period. Finally, BNP Paribas Arbitrage SNC increased its position in Albireo Pharma by 112.9% during the third quarter. BNP Paribas Arbitrage SNC now owns 13,840 shares of the biopharmaceutical company’s stock worth $268,000 after buying an additional 7,338 shares during the period. Institutional investors and hedge funds own 94.25% of the company’s stock.

About Albireo Pharma

(Get Rating)

Albireo Pharma, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. The company offers Bylvay for the treatment of progressive familial intrahepatic cholestasis, as well as in Phase III clinical trial for treating biliary atresia, alagille syndrome, and rare and life-threatening disorder to children; and Elobixibat for the treatment of chronic constipation and other functional diseases.